Search results
This test helps predict high-grade prostate cancer and can be applied as a marker of aggressiveness (McKiernan et al., 2018). With the same approach of markers associated with PCA3, MiPS (Mi Prostate Score Urine Test) stands out.
7 sie 2020 · Prolaris is a novel prognostic assay that measures tumor biology (cell-cycle progression score), in order to improve accuracy of risk stratification for men with localized prostate cancer. The Prolaris test combines the RNA expression levels of 31 genes involved in cell cycle progression and 15 housekeeping genes to generate a Prolaris Score™.
31 paź 2023 · PCA3, also known as DD3, is a prostate-specific mRNA biomarker that has promising potential for the detection of prostate cancer (PCa). Studies noted significantly higher PCA3 levels (10 to 100 times) in 53 out of 56 PCa tissue samples compared to adjacent non-cancerous prostate tissue.
7 lis 2020 · LDR BT uses permanent radioactive seeds implanted into the prostate, and is an option for those with low-risk and favourable intermediate-risk disease (low-volume GS 3 + 4), prostate volume <50 cm 3, and an International Prostate Symptom Score of ≤12 .
5 lis 2018 · Biomarkers for prostate cancer diagnosis and subsequent prognostic screening have significantly advanced this field. Here, we review some of the current blood, tissue, and urine biomarker tools used to measure an array of molecules including DNA, RNA, protein, or even epigenetic modifications.
6 lip 2023 · Due to its highly specific expression in prostate epithelial cells, NKX3.1 can be used as a diagnostic biomarker for prostate cancer and other metastatic lesions originating in the prostate. Some studies show that NKX3.1 offers improved sensitivity over PSA for the identification of poorly differentiated metastatic prostate cancer.
1 maj 2008 · Testing for prostate-specific antigen (PSA) has profoundly affected the diagnosis and treatment of prostate cancer. PSA testing has enabled physicians to detect prostate tumours while they...
